Tags

Type your tag names separated by a space and hit enter

Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.
World J Gastroenterol 2005; 11(45):7118-21WJ

Abstract

AIM

To assess the value of long-chain omega-3 fatty acids (FAs) supplementation in addition to amino-salicylic-acid (5-ASA) in pediatric patients with Crohn's disease (CD).

METHODS

Thirty-eight patients (20 males and 18 females, mean age 10.13 years, range 5-16 years) with CD in remission were randomized into two groups and treated for 12 mo. Group I (18 patients) received 5-ASA (50 mg/kg/d)+ omega-3 FAs as triglycerides in gastro-resistant capsules, 3 g/d (eicosapentanoic acid, EPA, 400 mg/g, docosahexaenoic acid, DHA, 200 mg/g). Group II (20 patients) received 5-ASA (50 mg/kg/d)+olive oil placebo capsules. Patients were evaluated for fatty acid incorporation in red blood cell membranes by gas chromatography at baseline 6 and 12 mo after the treatment.

RESULTS

The number of patients who relapsed at 1 year was significantly lower in group I than in group II (P<0.001). Patients in group I had a significant increase in the incorporation of EPA and DHA (P<0.001) and a decrease in the presence of arachidonic acids.

CONCLUSION

Enteric-coated omega-3 FAs in addition to treatment with 5-ASA are effective in maintaining remission of pediatric CD.

Authors+Show Affiliations

Pediatric Department, University of Messina, Italy. romanoc@unime.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

16437657

Citation

Romano, C, et al. "Usefulness of Omega-3 Fatty Acid Supplementation in Addition to Mesalazine in Maintaining Remission in Pediatric Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study." World Journal of Gastroenterology, vol. 11, no. 45, 2005, pp. 7118-21.
Romano C, Cucchiara S, Barabino A, et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol. 2005;11(45):7118-21.
Romano, C., Cucchiara, S., Barabino, A., Annese, V., & Sferlazzas, C. (2005). Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World Journal of Gastroenterology, 11(45), pp. 7118-21.
Romano C, et al. Usefulness of Omega-3 Fatty Acid Supplementation in Addition to Mesalazine in Maintaining Remission in Pediatric Crohn's Disease: a Double-blind, Randomized, Placebo-controlled Study. World J Gastroenterol. 2005 Dec 7;11(45):7118-21. PubMed PMID: 16437657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. AU - Romano,C, AU - Cucchiara,S, AU - Barabino,A, AU - Annese,V, AU - Sferlazzas,C, PY - 2006/1/27/pubmed PY - 2006/3/21/medline PY - 2006/1/27/entrez SP - 7118 EP - 21 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 11 IS - 45 N2 - AIM: To assess the value of long-chain omega-3 fatty acids (FAs) supplementation in addition to amino-salicylic-acid (5-ASA) in pediatric patients with Crohn's disease (CD). METHODS: Thirty-eight patients (20 males and 18 females, mean age 10.13 years, range 5-16 years) with CD in remission were randomized into two groups and treated for 12 mo. Group I (18 patients) received 5-ASA (50 mg/kg/d)+ omega-3 FAs as triglycerides in gastro-resistant capsules, 3 g/d (eicosapentanoic acid, EPA, 400 mg/g, docosahexaenoic acid, DHA, 200 mg/g). Group II (20 patients) received 5-ASA (50 mg/kg/d)+olive oil placebo capsules. Patients were evaluated for fatty acid incorporation in red blood cell membranes by gas chromatography at baseline 6 and 12 mo after the treatment. RESULTS: The number of patients who relapsed at 1 year was significantly lower in group I than in group II (P<0.001). Patients in group I had a significant increase in the incorporation of EPA and DHA (P<0.001) and a decrease in the presence of arachidonic acids. CONCLUSION: Enteric-coated omega-3 FAs in addition to treatment with 5-ASA are effective in maintaining remission of pediatric CD. SN - 1007-9327 UR - http://www.unboundmedicine.com/medline/citation/16437657/full_citation L2 - http://www.wjgnet.com/1007-9327/full/v11/i45/7118.htm DB - PRIME DP - Unbound Medicine ER -